Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study

Εμφάνιση άλλων εκδόσεων (1)

We report clinical safety and biochemical efficacy from a dose-ranging study of intravenously administered AVI-4658 phosphorodiamidate morpholino oligomer (PMO) in patients with Duchenne muscular dystrophy. We undertook an open-label, phase 2, dose-escalation study (0·5, 1·0, 2·0, 4·0, 10·0, and 20·...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K, Abbs, S, Garralda, M, Bourke, J, Wells, D, Dickson, G, Wood, M, Wilton, S, Straub, V, Kole, R, Shrewsbury, S, Sewry, C, Morgan, J, Bushby, K, Muntoni, F
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2011

Παρόμοια τεκμήρια

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
ανά: Cirak, S, κ.ά.
Έκδοση: (2011)

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
ανά: Kinali, M, κ.ά.
Έκδοση: (2009)

Rescu of severely affected dystrophin/utrophin deficient mice by morpholino-oligomer mediated exon skipping
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2010)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2010)

Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
ανά: Li, Chengxi, κ.ά.
Έκδοση: (2021)

Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency
ανά: Yin, HF, κ.ά.
Έκδοση: (2016)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
ανά: Frank, DE, κ.ά.
Έκδοση: (2020)

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
ανά: Yokota, T, κ.ά.
Έκδοση: (2012)

Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
ανά: Betts, C, κ.ά.
Έκδοση: (2014)

Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies
ανά: Janghra, N, κ.ά.
Έκδοση: (2016)

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
ανά: Lu, Q, κ.ά.
Έκδοση: (2003)

Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice
ανά: Forand, A, κ.ά.
Έκδοση: (2020)

Muscle X-inactivation patterns and dystrophin expression in Duchenne muscular dystrophy carriers.
ανά: Matthews, P, κ.ά.
Έκδοση: (1995)

Use of antisense-mediated exon skipping to generate dystrophin in muscles of the mdx dystrophic mouse
ανά: Lu, Q, κ.ά.
Έκδοση: (2004)

Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
ανά: Nowak, K, κ.ά.
Έκδοση: (2004)

The Duchenne and Becker muscular dystrophy gene and protein product dystrophin
ανά: Monaco, A
Έκδοση: (1989)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
ανά: Guiraud, S, κ.ά.
Έκδοση: (2019)

Dystrophin, the protein product of the Duchenne/Becker muscular dystrophy gene.
ανά: Monaco, A
Έκδοση: (1989)

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
ανά: Yin, H, κ.ά.
Έκδοση: (2009)

Harnessing the potential of dystrophin-related proteins for ameliorating Duchenne's muscular dystrophy.
ανά: Krag, T, κ.ά.
Έκδοση: (2001)

Micro-dystrophin genes bring hope of an effective therapy for duchenne muscular dystrophy
ανά: Davies, K, κ.ά.
Έκδοση: (2019)

Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy.
ανά: Griffin, J, κ.ά.
Έκδοση: (2002)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
ανά: Aoki, Y, κ.ά.
Έκδοση: (2012)

Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
ανά: Straub, V, κ.ά.
Έκδοση: (2016)

Absence of the dystrophin protein in Duchenne muscular dystrophy: effects on transcriptome, proteome and microRNA secretome
ανά: van Westering, T
Έκδοση: (2018)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2010)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
ανά: Aoki, Y, κ.ά.
Έκδοση: (2011)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2011)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2009)

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
ανά: Wang, Q, κ.ά.
Έκδοση: (2010)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
ανά: Blain, A, κ.ά.
Έκδοση: (2018)

Dystrophin gene analysis in Duchenne/Becker dystrophy in a Malaysian population using multiplex polymerase chain reaction
ανά: Tan, J., κ.ά.
Έκδοση: (2010)

Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy
ανά: Perkins, K, κ.ά.
Έκδοση: (2018)

RNA-seq analysis of an antisense sequence optimized for exon skipping in Duchenne patients reveals no off-target effect
ανά: Domenger, C, κ.ά.
Έκδοση: (2017)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2012)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2012)

In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
ανά: Aoki, Y, κ.ά.
Έκδοση: (2010)

Guidelines for morpholino use in zebrafish
ανά: Stainier, Didier Y. R., κ.ά.
Έκδοση: (2018)

Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2011)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
ανά: Betts, C, κ.ά.
Έκδοση: (2018)